budoprutug
Monoclonal antibody
Evidence outlook
Primary Membranous Nephropathy: topline reported 2026-10-24
The sponsor reported topline results on 2026-10-24 (Initial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission). The announcement is listed under Regulatory events.
Also in development:Systemic Lupus Erythematosus · Phase 1/2
Company guidance: data expected in 2027 (NCT07096843; Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗
Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Budoprutug SC: Future Direction Data in NHPs and healthy volunteers support continued development of SC formulation, with plans to advance to a study in patients to confirm dose and regimen with initial data expected in 2027 NHPs = nonhuman primates, PD = pharmacodynamic, SC = subcutaneous Next Steps Non-Human Primates Data confirmed bioavailability and favorable safety/tolerability Evaluation of SC formulation at full B-cell depleting dose regimen in patients with autoimmune diseases Healthy Volunteers (low dose) Robust PD effects support continued clinical development” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PrisMN NCT07096843 · Primary Membranous Nephropathy Registry: NCT07096843 | 2 | Incidence of Treatment-Emergent Adverse Events (TEAEs) (Up to Week 48) 2027-10 | In progress: results expected 1 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, Tafasitamab, cemacabtagene ansegedleucel, FT819 and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.
This drug's own stage for Primary Membranous Nephropathy: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Budoprutug: this drug | Phase 2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Felzartamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab Beta (Bejescin) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Povetacicept | Phase 2/3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| ALXN1920 | Phase 2 | Protein / enzyme therapeutic | Complement factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow budoprutug to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
April 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent